secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001193125-26-142947
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics amends CEO and executive severance, equity acceleration provisions
--------------------------------------------------------------------------------

- CEO Craig Collard's amended agreement: severance of 1x base salary + bonus (non-CIC) or 2x (CIC), plus equity acceleration.
- For performance-based equity granted after April 3, 2026, vesting accelerates at greater of actual performance or target upon qualifying termination.
- Similar amendments for CFO Duarte, CDO Forbes, COO Hensley: 12 months pay & equity (non-CIC) or 24 months & full acceleration (CIC).
- Agreements add 24-month non-competition and non-solicitation covenants; governing law changed to North Carolina.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526142947/0001193125-26-142947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526142947/hrtx-20260403.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-142947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer